| Survival: | N/R |
| Toxicity Grade: | 4 |
| Treatments: | Biologic therapy |
| Drugs: | |
| Country: | Netherlands |
| City/State/Province: | Rotterdam |
| Hospital: | Erasmus Medical Center |
| Journal: | Link |
| Date: | 2/2005 |
| Description: |
| Patients: This Phase I study involved 38 patients with various advanced or metastatic solid tumors. Two of the 38 patients had mesothelioma. Overall, twenty-six patients were men, and 12 were women. The median age was 55 years. Treatment: The treatment consisted of a matrix metalloproteinase inhibitor called CP-471,358. Matrix metalloproteinases (MMP’s) play a role in tissue remodeling, scar formation, and fracture healing. In cancer, MMP’s facilitate metastasis. Toxicities: The only grade 4 toxicity was elevated bilirubin. Other toxicities included: grade 1-3 myalgia, arthralgia, diarrhea, nausea, and asthenia. The frequency of myalgia, and arthralgia and the difficulty in controlling these symptoms led the authors to recommend that this agent not be used for further study in cancer patients. Results: No partial or complete responses were observed. Support: Three of eight authors of the study are either employed or affiliated with Pfizer Global Research and Development. Pfizer manufactures and/or markets CP-471,358. Correspondence: Andre Planting, MD. |